Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: aldesleukin
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: in vitro treated peripheral blood stem cell transplantation

First Posted Date: 2006-01-11

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 21

Registration Number: NCT00274846

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Rituximab

First Posted Date: 2006-01-11

Last Posted Date: 2019-05-23

Lead Sponsor: German CLL Study Group

Target Recruit Count: 825

Registration Number: NCT00275054

Locations: 🇦🇹
Universitaetsklinik fuer Innere Medizin I, Vienna, Austria
🇫🇷
CHU Poitiers, Poitiers, France
🇩🇪
St. Hedwig Krankenhaus, Berlin, Germany

and more 84 locations

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: carboplatin
Drug: prednisone
Drug: etoposide
Drug: vincristine
Drug: ifosfamide

First Posted Date: 2006-01-11

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 100

Registration Number: NCT00274924

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 99 locations

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2005-12-29

Last Posted Date: 2012-04-06

Lead Sponsor: Keio University

Target Recruit Count: 33

Registration Number: NCT00270881

Locations: 🇯🇵
Keio University School of Medicine, Tokyo, Japan

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasm

Interventions: Drug: epirubicin
Drug: cyclophosphamide
Drug: docetaxel
Drug: trastuzumab

First Posted Date: 2005-12-29

Last Posted Date: 2012-03-20

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 30

Registration Number: NCT00270894

Locations: 🇺🇸
Arena Oncology Associates, Great Neck, New York, United States
🇺🇸
Advanced Medical Specialties, Miami, Florida, United States
🇺🇸
Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States

and more 4 locations

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-12-15

Last Posted Date: 2012-10-26

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 3500

Registration Number: NCT00266136

Locations: 🇩🇪
University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology, Muenster, Germany

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy